Whalesbook
Tariffs Prompt Pharma Supply Chain Shift
The U.S. decision to impose tariffs on patented drug ingredients and intermediates signals major changes in how global pharmaceutical supply chains operate. For India's growing Contract Development and Manufacturing Organization (CDMO) sector, this policy shift is more than just immediate costs; it requires a strategic change focused on long-term stability and adapting to global politics. While immediate impacts on profits are predicted to be modest, the larger consequence is the growing importance of manufacturing in the U.S. or specific countries. This creates different levels of risk for Indian CDMOs. Those working with smaller biotech firms face higher exposure than those partnered with large pharmaceutical companies that have special trade deals with the U.S.
Uneven Impact and Market Reaction
The proposed tariffs, which can range from zero to 100 percent, mainly target branded medicines from innovators who haven't secured special U.S. trade deals or committed to U.S. manufacturing. This indirect impact will affect Indian CDMOs even if they don't send finished drugs to the U.S. Analysts expect a modest, mid-single digit impact on profits across the industry, rather than a crisis. However, some companies are more vulnerable than others. Sai Life Sciences and Anthem Biosciences, which work closely with smaller biotech firms less likely to have U.S. trade agreements, could see EBITDA impacts of 6-8 percent. In contrast, Divi's Laboratories, with less than 10% of its revenue from the U.S. and key clients like Eli Lilly having favorable trade terms, anticipates a 4-5% EBITDA impact. Piramal Pharma's CDMO business, with half its operations abroad, expects a 5-6% impact, while Laurus Labs sees a lower exposure of 1-2 percent.
Market reactions reflect these varied risks. Piramal Pharma's stock saw a slight dip of -0.353% on April 7, 2026, trading around ₹141.04. Sai Life Sciences traded around ₹959.95, having fallen -1.73% on April 2, 2026. Divi's Laboratories, with a P/E of approximately 62.72, traded near ₹5,856.50. Laurus Labs, with a P/E around 67.88, was priced at ₹1058.2. Historically, Indian pharma stocks have reacted to U.S. tariff news, with previous threats in early 2025 causing temporary drops.
Growth, Competition, and Shifting Trends
The broader Indian CDMO market is projected to grow at a strong 13.4% annually, driven by global outsourcing and efforts to diversify supply chains away from China. Indian CDMOs have historically gained from such shifts, securing more U.S.-focused contracts due to earlier tariffs. U.S.-based CDMOs have also grown, supported by pressure to bring manufacturing back home. High valuations reflect strong growth expectations and market standing. Sai Life Sciences, with a P/E of around 60.2x, appears high compared to the Asian Life Sciences industry average of 38.2x and its peers at 42.6x. Divi's Laboratories and Laurus Labs trade at P/E ratios of approximately 65.0x and 67.74x respectively, indicating their established positions.
Despite the current exemption for generics, the U.S. focus on national security means a long-term push for domestic drug production. This strategy aims to lessen reliance on foreign sources and encourage U.S. manufacturing. While Indian exports to the U.S. have historically remained strong, past tariff threats have caused significant market pullbacks. For instance, India's total exports to the U.S. dropped by 37.5% between May and September 2025 due to rising duties. The current exclusion of generics is vital, as they make up nearly 90% of U.S. drug use, with India supplying about 40% of these by volume.
Key Risks: Client Ties and Sourcing Changes
The main risk for Indian CDMOs is not just passing on tariff costs but potentially disrupting existing client relationships and contracts. Companies relying heavily on small-to-mid-sized biotech firms—which are less able to absorb costs or agree to special U.S. trade terms—face a more uncertain future. The push for U.S. manufacturing also means that simply having factories in India might not be enough. The U.S. administration's long-term plan is to encourage domestic production and investment. This could increase pressure on upstream suppliers, even if they are not directly taxed. Furthermore, contract clauses like passing costs on are not perfect solutions and could lead to lengthy negotiations or loss of business if clients seek more stable supply chains closer to home. Reliance on the U.S. market, which accounts for a large part of Indian pharma exports, remains a fundamental weakness.
Future Strategies: U.S. Investment and New Models
The future for Indian CDMOs will likely involve investing together in U.S. facilities, using 'dual-shore' production, or acquiring U.S. companies to build a presence there. Companies are already preparing for geopolitics to be a permanent factor in pharma supply chains, leading to proactive changes. While analysts are calm about immediate financial damage, the strategic impacts are significant. The trend toward reducing supply chain risks and diversifying is expected to continue driving growth in the Indian CDMO sector, but adapting to changing trade rules and customer needs will be crucial for maintaining competitiveness and market share against strong U.S. manufacturing policy.